Biosimilars: Expanding Drug Availability And Cutting Costs

ACHP calls on Congress to increase access to biosimilars by redefining interchangeability requirements and addressing outdated regulations, skewed incentives and PBM practices that intentionally slow their adoption. 

Loader Loading...
EAD Logo Taking too long?
Reload Reload document
| Open Open in new tab
icon-arrow
client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo client-logo
icon-arrow